![](/img/cover-not-exists.png)
C25Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study
Pronzato, P, Mustacchi, G, Riccardi, F, Turletti, A, Michelotti, A, Natoli, C, Livi, L, Del Mastro, L, Donadio, M, Garrone, O, Giordano, M, De Laurentiis, M, Marchetti, P, Montemurro, F, Romagnoli, E,Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx424.024
Date:
October, 2017
File:
PDF, 49 KB
english, 2017